Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Insulet Corporation (PODD) Announces Strategic Expansion and Supply Agreement Update
Insulet Corporation (PODD) Announces Strategic Expansion and Supply Agreement Update
Abdul Rahman
Sun, February 15, 2026 at 8:53 PM GMT+9 2 min read
In this article:
PODD
+0.80%
Insulet Corporation (NASDAQ:PODD) is one of the best medical technology stocks to invest in. On February 5, Insulet Corporation (NASDAQ:PODD) announced that its Omnipod 5 Automated Insulin Delivery (AID) system is now commercially available in the Middle East. The specific countries mentioned were the United Arab Emirates (UAE), Saudi Arabia, Qatar, and Kuwait.
Insulet Corporation (PODD) Announces Strategic Expansion and Supply Agreement Update
Pixabay/Public Domain
According to Insulet, the Omnipod 5 system automatically adjusts insulin delivery every five minutes. It achieves this by communicating with compatible continuous glucose monitoring sensors and is designed to eliminate the need for multiple daily injections, simplifying diabetes management, noted Insulet.
The company also launched Omnipod Discover, a web-based data management and analytics platform for users, caregivers, and healthcare providers. It organizes and visualizes glucose and insulin delivery data to support diabetes care decisions.
In a separate update, on February 3, Insulet entered into an addendum to its existing Purchase Agreement with NXP USA, Inc. The addendum is effective from January 1, 2026, and extends a long-term supply arrangement that was originally established on October 12, 2017.
Some of the elements amended in the updated agreement include pricing terms, product volume commitments, and product order flexibility. Others are contractual conditions that affect Insulet’s supply chain planning.
According to Insulet, the updated terms are intended to maintain continuity of supply for components used in its medical devices. They also provide revised commercial terms that may affect cost structure and operational flexibility.
Insulet Corporation (NASDAQ:PODD) designs, manufactures, and sells insulin delivery systems for people with diabetes. Its flagship product is the Omnipod Insulin Management System, a tubeless, wearable insulin pump that provides continuous subcutaneous insulin infusion and integrates with glucose monitoring technologies.
While we acknowledge the potential of PODD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
**READ NEXT: ****12 Best Foreign Stocks to Buy Right Now and **11 Best AI Penny Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Terms and Privacy Policy
Privacy Dashboard
More Info